barbadin

interferes with beta-arrestin and beta2-adaptin subunit interaction

Also Known As:

3-Amino-5-(4-benzylphenyl)thieno(2,3-d)pyrimidin-4(3H)-one; thieno(2,3-d)pyrimidin-4(3H)-one, 3-amino-5-(4-(phenylmethyl)phenyl)-

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - barbadin: 2

Experts

1.	Abouda, Mohamed: 1 article (03/2021)
2.	Donia, Thoria: 1 article (03/2021)
3.	Hessien, Mohamed: 1 article (03/2021)
4.	Kelany, Mohamed: 1 article (03/2021)
5.	Fukuda, Makoto: 1 article (01/2021)
6.	He, Yang: 1 article (01/2021)
7.	He, Yanlin: 1 article (01/2021)
8.	Liang, Chen: 1 article (01/2021)
9.	Liu, Hailan: 1 article (01/2021)
10.	Liu, Hesong: 1 article (01/2021)

Related Diseases

1.	Weight Loss (Weight Reduction) 01/01/2021 - "Thus, our results prove the concept that inhibition of 5-HT2CR desensitization can be a valid strategy to improve the long-term weight loss effects of Lor or other 5-HT2CR agonists, and also provide an intellectual framework to develop effective long-term management of weight by targeting 5-HT2CR desensitization.SIGNIFICANCE STATEMENT By demonstrating that the combination of barbadin (Bar) with a G-protein-coupled receptor (GPCR) agonist can provide prolonged weight-lowering benefits in a preclinical setting, our work should call for additional efforts to validate Bar as a safe and effective medicine or to use Bar as a lead compound to develop more suitable compounds for obesity treatment. " 01/01/2021 - "Barbadin Potentiates Long-Term Effects of Lorcaserin on POMC Neurons and Weight Loss."
2.	Obesity 01/01/2021 - "Thus, our results prove the concept that inhibition of 5-HT2CR desensitization can be a valid strategy to improve the long-term weight loss effects of Lor or other 5-HT2CR agonists, and also provide an intellectual framework to develop effective long-term management of weight by targeting 5-HT2CR desensitization.SIGNIFICANCE STATEMENT By demonstrating that the combination of barbadin (Bar) with a G-protein-coupled receptor (GPCR) agonist can provide prolonged weight-lowering benefits in a preclinical setting, our work should call for additional efforts to validate Bar as a safe and effective medicine or to use Bar as a lead compound to develop more suitable compounds for obesity treatment. "
3.	Triple Negative Breast Neoplasms 03/15/2021 - "We used Barbadin to selectively inhibit β-Arr/AP2 interaction in AVP-stimulated V2R receptor of triple-negative breast cancer cells (MDA MB-231). "
4.	Body Weight (Weight, Body) 01/01/2021 - "Here, we show that barbadin (Bar), a novel β-arrestin/β2-adaptin inhibitor, can prevent 5-HT2CR internalization in cells and potentiate long-term effects of Lor to reduce appetite and body weight in male mice. "

Related Drugs and Biologics

1.	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)
2.	Arrestin
3.	Pro-Opiomelanocortin (Proopiomelanocortin)
4.	lorcaserin